Sandeep Vaid, MD
Neurology · Lawrenceville, GANPI 1851684245
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,304 of the $16,004 with a category attached, or 70.6%. It is spread thinly across 60 manufacturers, the largest accounting for just 18.7%. Reporting peaked in 2022 at $5,447 and has fallen 87.9% since, to $661 in 2025.
Across 530 payments — averaging $30.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- MML US, Inc.$3K
- Abbott$2K
- Amgen$1K
- Saluda Medical Americas, Inc.$1K
- Medtronic$803
- AbbVie$787
- plus $7K from 54 others
Across 290 payments — averaging $14,367 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$2.7M
- Endo Pharmaceuticals Inc.$398K
- MML US, Inc.$285K
- Scilex Pharmaceuticals Inc.$148K
- GRT US Holding, Inc.$147K
- Mesoblast, Inc.$143K
- plus $295K from 12 others
What the payments were for
- Travel & lodging$4,49928%
- Food & beverage$11,30471%
- Education$2011%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ReActiv8$2,681
- KRYSTEXXA$1,113
- Evoke SCS$817
- Proclaim Family of SCS IPGs$666
- INTELLIS ADAPTIVESTIM$466
- SiJoin, VerteLoc$263
- Proclaim IPG$246
- PAINTEQ$234
- Omnia$186
- PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A$163
- mild Device Kit$150
- SPRINT PNS System$149
- PROCLAIM$106
How this compares
$16,004 in reported general payments places this provider in the 80th percentile of 506 neurology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 128 | $83,873 |
| Buprenorphine | 205 | $58,869 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 1,346 | $53,127 |
| UbrelvyUbrogepant | 20 | $42,319 |
| RelistorMethylnaltrexone Bromide | 14 | $37,356 |
| Xtampza ErOxycodone Myristate | 74 | $33,049 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,097 | $23,868 |
| Nurtec OdtRimegepant Sulfate | 17 | $23,198 |
| OxycontinOxycodone Hcl | 33 | $13,241 |
| NucyntaTapentadol Hcl | 14 | $12,160 |
| Emgality PenGalcanezumab-Gnlm | 14 | $12,126 |
| Aimovig AutoinjectorErenumab-Aooe | 13 | $10,906 |
| Pregabalin | 496 | $9,261 |
| LyricaPregabalin | 11 | $8,253 |
| Oxycodone Hcl | 400 | $7,454 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er, Nucynta | $765 | $129,082216 claims |
| Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate | $36 | $59,458233 claims |
| AbbVieUbrelvy | $787 | $42,31920 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $576 | $37,35614 claims |
| PfizerNurtec Odt, Lyrica | $302 | $31,45228 claims |
| Redhill Biopharma Inc.Movantik | $94 | $5,84215 claims |
| Upsher-smith Laboratories LLCTopiramate | $251 | $27344 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 506 neurology providers in Georgia.
Other neurology in Lawrenceville
- Dinesh RajuLawrenceville$414K
- Mitzi WilliamsSmyrna$1.4M
- Joash LazarusAtlanta$1.1M
- Jeffrey EnglishAtlanta$749K
- John MorganAugusta$715K
- Frank BerensonAtlanta$527K
- Julio FlaminiAtlanta$501K
- Douglas StuartAtlanta$493K
- Sudhir AthniMacon$432K
- Victor RosenfeldSavannah$413K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.